244 related articles for article (PubMed ID: 32152065)
1. The Evolving Role of Calcineurin Inhibitors in Treating Lupus Nephritis.
Peleg Y; Bomback AS; Radhakrishnan J
Clin J Am Soc Nephrol; 2020 Jul; 15(7):1066-1072. PubMed ID: 32152065
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive treatment for proliferative lupus nephritis.
Tunnicliffe DJ; Palmer SC; Henderson L; Masson P; Craig JC; Tong A; Singh-Grewal D; Flanc RS; Roberts MA; Webster AC; Strippoli GF
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD002922. PubMed ID: 29957821
[TBL] [Abstract][Full Text] [Related]
3. Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis.
Mok CC
Nephrol Dial Transplant; 2016 Oct; 31(10):1561-6. PubMed ID: 27591327
[TBL] [Abstract][Full Text] [Related]
4. Moderator's view: The use of calcineurin inhibitors in the treatment of lupus nephritis.
Kronbichler A; Neumann I; Mayer G
Nephrol Dial Transplant; 2016 Oct; 31(10):1572-6. PubMed ID: 27591329
[TBL] [Abstract][Full Text] [Related]
5. Con: The use of calcineurin inhibitors in the treatment of lupus nephritis.
Fernandez Nieto M; Jayne DR
Nephrol Dial Transplant; 2016 Oct; 31(10):1567-71. PubMed ID: 27591328
[TBL] [Abstract][Full Text] [Related]
6. The effect of calcineurin inhibitors in the induction and maintenance treatment of lupus nephritis: a systematic review and meta-analysis.
Zhang X; Ji L; Yang L; Tang X; Qin W
Int Urol Nephrol; 2016 May; 48(5):731-43. PubMed ID: 26781720
[TBL] [Abstract][Full Text] [Related]
7. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.
Fanouriakis A; Kostopoulou M; Cheema K; Anders HJ; Aringer M; Bajema I; Boletis J; Frangou E; Houssiau FA; Hollis J; Karras A; Marchiori F; Marks SD; Moroni G; Mosca M; Parodis I; Praga M; Schneider M; Smolen JS; Tesar V; Trachana M; van Vollenhoven RF; Voskuyl AE; Teng YKO; van Leew B; Bertsias G; Jayne D; Boumpas DT
Ann Rheum Dis; 2020 Jun; 79(6):713-723. PubMed ID: 32220834
[TBL] [Abstract][Full Text] [Related]
8. Lupus nephritis: induction therapy in severe lupus nephritis--should MMF be considered the drug of choice?
Rovin BH; Parikh SV; Hebert LA; Chan TM; Mok CC; Ginzler EM; Hooi LS; Brunetta P; Maciuca R; Solomons N
Clin J Am Soc Nephrol; 2013 Jan; 8(1):147-53. PubMed ID: 22879439
[TBL] [Abstract][Full Text] [Related]
9. Treatment for lupus nephritis.
Henderson L; Masson P; Craig JC; Flanc RS; Roberts MA; Strippoli GF; Webster AC
Cochrane Database Syst Rev; 2012 Dec; 12():CD002922. PubMed ID: 23235592
[TBL] [Abstract][Full Text] [Related]
10. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.
Rovin BH; Solomons N; Pendergraft WF; Dooley MA; Tumlin J; Romero-Diaz J; Lysenko L; Navarra SV; Huizinga RB;
Kidney Int; 2019 Jan; 95(1):219-231. PubMed ID: 30420324
[TBL] [Abstract][Full Text] [Related]
11. Induction and Maintenance Immunosuppression Treatment of Proliferative Lupus Nephritis: A Network Meta-analysis of Randomized Trials.
Palmer SC; Tunnicliffe DJ; Singh-Grewal D; Mavridis D; Tonelli M; Johnson DW; Craig JC; Tong A; Strippoli GFM
Am J Kidney Dis; 2017 Sep; 70(3):324-336. PubMed ID: 28233655
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis.
Choi CB; Won S; Bae SC
Lupus; 2018 May; 27(6):1007-1011. PubMed ID: 29448881
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis.
Walsh M; James M; Jayne D; Tonelli M; Manns BJ; Hemmelgarn BR
Clin J Am Soc Nephrol; 2007 Sep; 2(5):968-75. PubMed ID: 17702723
[TBL] [Abstract][Full Text] [Related]
14. An Update on the Diagnosis and Management of Lupus Nephritis.
Kostopoulou M; Adamichou C; Bertsias G
Curr Rheumatol Rep; 2020 Jun; 22(7):30. PubMed ID: 32500443
[TBL] [Abstract][Full Text] [Related]
15. Combined immunosuppressive treatment (CIST) in lupus nephritis: a multicenter, randomized controlled study.
An Y; Zhou Y; Bi L; Liu B; Wang H; Lin J; Xu D; Wang M; Zhang J; Wang Y; An Y; Zhu P; Xie R; Zhang Z; Mei Y; Liu X; Deng X; Yao Z; Zhang Z; Wang Y; Xiao W; Shen H; Yang X; Xu H; Yu F; Wang G; Lu X; Li Y; Li Y; Zuo X; Li Y; Liu Y; Zhao Y; Guo J; Sun L; Zhao M; Li Z
Clin Rheumatol; 2019 Apr; 38(4):1047-1054. PubMed ID: 30488367
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.
Ginzler EM; Dooley MA; Aranow C; Kim MY; Buyon J; Merrill JT; Petri M; Gilkeson GS; Wallace DJ; Weisman MH; Appel GB
N Engl J Med; 2005 Nov; 353(21):2219-28. PubMed ID: 16306519
[TBL] [Abstract][Full Text] [Related]
17. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials.
Henderson LK; Masson P; Craig JC; Roberts MA; Flanc RS; Strippoli GF; Webster AC
Am J Kidney Dis; 2013 Jan; 61(1):74-87. PubMed ID: 23182601
[TBL] [Abstract][Full Text] [Related]
18. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Höcker B; Tönshoff B
Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of cyclophosphamide and non-cyclophosphamide in the induction therapy of Malaysian lupus nephritis patients.
Rosli FZ; Shaharir SS; Abdul Gafor AH; Mohd R; Aizuddin AN; Osman S
Lupus; 2022 Aug; 31(9):1138-1146. PubMed ID: 35608373
[TBL] [Abstract][Full Text] [Related]
20. Recent news in the treatment of lupus nephritis.
Tesar V; Hruskova Z
Minerva Med; 2012 Aug; 103(4):235-51. PubMed ID: 22805617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
